<p>The GenHAT study is an ancillary pharmacogenomics study to the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT was a randomized, double-blind, multi-center trial that enrolled 42,418 participants ≥55 years of age with hypertension and at least one additional risk factor for cardiovascular disease (CVD). Participants were randomized to treatment with one of four primary antihypertensive drugs: chlorthalidone (thiazide-like diuretic), amlodipine (CCB), lisinopril (ACE-i), or doxazosin (alpha-adrenergic blocker) in a ratio of 1.7:1:1:1, respectively. Participants were followed for treatment response and CVD outcomes.  The original GenHAT study (N=39,114) evaluated the association of candidate hypertensive genetic variants with CVD outcomes for participants consenting to genetic research. The current GWAS study focuses on a subset of African American GenHAT participants (n=6908).  </p>

Genetics of Hypertension Associated Treatment (GenHAT) Study, Genomic    Background of Blood Pressure Response to Treatment in African    Americans

Blood Pressure study with SNP Genotypes (Array) data on dbGaP (6,908 participants)

phs002716 — Genetics of Hypertension Associated Treatment (GenHAT) Study, Genomic    Background of Blood Pressure Response to Treatment in African    Americans

Genetics of Hypertension Associated Treatment (GenHAT) Study, Genomic Background of Blood Pressure Response to Treatment in African Americans

Description

Applying For Access

Summary